Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Gonzalez-Angulo, A M; Parinyanitikul, N; Lei, X; Mittendorf, E A; Zhang, H; Valero, V; Hunt, K K; Hortobagyi, G N; Chavez-MacGregor, M.

Br J Cancer ; 112(4): 630-5, 2015 Feb 17.

Artículo en Inglés | MEDLINE | ID: mdl-25584488

2.

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

Kim, M M; Allen, P; Gonzalez-Angulo, A M; Woodward, W A; Meric-Bernstam, F; Buzdar, A U; Hunt, K K; Kuerer, H M; Litton, J K; Hortobagyi, G N; Buchholz, T A; Mittendorf, E A.

Ann Oncol ; 24(8): 1999-2004, 2013 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-23562929

3.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes, F A; Walters, R S; Theriault, R L; Forman, A D; Newton, L K; Raber, M N; Buzdar, A U; Frye, D K; Hortobagyi, G N.

J Natl Cancer Inst ; 83(24): 1797-805, 1991 Dec 18.

Artículo en Inglés | MEDLINE | ID: mdl-1683908

4.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Hortobagyi, G N; Buzdar, A U; Theriault, R L; Valero, V; Frye, D; Booser, D J; Holmes, F A; Giralt, S; Khouri, I; Andersson, B; Gajewski, J L; Rondon, G; Smith, T L; Singletary, S E; Ames, F C; Sneige, N; Strom, E A; McNeese, M D; Deisseroth, A B; Champlin, R E.

J Natl Cancer Inst ; 92(3): 225-33, 2000 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-10655439

5.

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu, D; Liu, B; Jing, T; Sun, D; Price, J E; Singletary, S E; Ibrahim, N; Hortobagyi, G N; Hung, M C.

Oncogene ; 16(16): 2087-94, 1998 Apr 23.

Artículo en Inglés | MEDLINE | ID: mdl-9572489

6.

Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.

Ang, P T; Buzdar, A U; Smith, T L; Kau, S; Hortobagyi, G N.

J Clin Oncol ; 7(11): 1677-84, 1989 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-2809682

7.

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

Diamandidou, E; Buzdar, A U; Smith, T L; Frye, D; Witjaksono, M; Hortobagyi, G N.

J Clin Oncol ; 14(10): 2722-30, 1996 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-8874333

8.

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

Hortobagyi, G N; Bodey, G P; Buzdar, A U; Frye, D; Legha, S S; Malik, R; Smith, T L; Blumenschein, G R; Yap, H Y; Rodriguez, V.

J Clin Oncol ; 5(3): 354-64, 1987 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-3819804

9.

High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.

Hortobagyi, G N; Buzdar, A U; Bodey, G P; Kau, S; Rodriguez, V; Legha, S S; Yap, H Y; Blumenschein, G R.

J Clin Oncol ; 5(2): 178-84, 1987 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-3543241

10.

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Valero, V; Holmes, F A; Walters, R S; Theriault, R L; Esparza, L; Fraschini, G; Fonseca, G A; Bellet, R E; Buzdar, A U; Hortobagyi, G N.

J Clin Oncol ; 13(12): 2886-94, 1995 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-8523051

11.

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

Rahman, Z U; Frye, D K; Buzdar, A U; Smith, T L; Asmar, L; Champlin, R E; Hortobagyi, G N.

J Clin Oncol ; 15(10): 3171-7, 1997 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9336352

12.

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

Valero, V; Jones, S E; Von Hoff, D D; Booser, D J; Mennel, R G; Ravdin, P M; Holmes, F A; Rahman, Z; Schottstaedt, M W; Erban, J K; Esparza-Guerra, L; Earhart, R H; Hortobagyi, G N; Burris, H A.

J Clin Oncol ; 16(10): 3362-8, 1998 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9779713

13.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

Buzdar, A U; Singletary, S E; Theriault, R L; Booser, D J; Valero, V; Ibrahim, N; Smith, T L; Asmar, L; Frye, D; Manuel, N; Kau, S W; McNeese, M; Strom, E; Hunt, K; Ames, F; Hortobagyi, G N.

J Clin Oncol ; 17(11): 3412-7, 1999 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-10550135

14.

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Zhang, L; Lau, Y K; Xia, W; Hortobagyi, G N; Hung, M C.

Clin Cancer Res ; 5(2): 343-53, 1999 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10037184

15.

Management of breast cancer: status and future trends.

Hortobagyi, G N.

Semin Oncol ; 22(5 Suppl 12): 101-7, 1995 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-7481851

16.

Optimal duration of therapy with trastuzumab.

Hortobagyi, G N.

Semin Oncol ; 28(5 Suppl 16): 33-40, 2001 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-11706394

17.

Recent progress in the clinical development of docetaxel (Taxotere).

Hortobagyi, G N.

Semin Oncol ; 26(3 Suppl 9): 32-6, 1999 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-10426457

18.

Single-agent paclitaxel for the treatment of breast cancer: an overview.

Hortobagyi, G N; Holmes, F A.

Semin Oncol ; 23(1 Suppl 1): 4-9, 1996 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-8629036

19.

Paclitaxel-containing combination chemotherapy for metastatic breast cancer.

Hortobagyi, G N; Ibrahim, N.

Semin Oncol ; 23(1 Suppl 1): 53-7, 1996 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-8629039

20.

Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.

Hortobagyi, G N; Holmes, F A; Theriault, R L; Rahman, Z; Buzdar, A U.

Semin Oncol ; 24(4 Suppl 11): S11-13-S11-19, 1997 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9314293

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy.

Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.

Management of breast cancer: status and future trends.

Optimal duration of therapy with trastuzumab.

Recent progress in the clinical development of docetaxel (Taxotere).

Single-agent paclitaxel for the treatment of breast cancer: an overview.

Paclitaxel-containing combination chemotherapy for metastatic breast cancer.

Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.